Paper24480331
Hydrodynamic transfection for generation of novel mouse models for liver cancer research.
Chen X and 1 other. Am J Pathol, 2014. Cited by 343 papers, by iCite.
Cite this record
ConductScience Library. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Papers, record 24480331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24480331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hydrodynamic transfection for generation of novel mouse models for liver cancer research.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Disease Models, Animal | Major topic |
| Hydrodynamics | Major topic |
| Liver Neoplasms | Major topic |
| Transfection | Major topic |
| Animals | |
| Mice |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 DK026743 | NIDDK NIH HHS | United States | P30DK026743 | PubMed and NIH | NIH RePORTER |
| R01 CA136606 | NCI NIH HHS | United States | R01CA136606 | PubMed and NIH | NIH RePORTER |
| R01CA136606 | NCI NIH HHS | United States | R01CA136606 | PubMed and NIH | NIH RePORTER |
References103
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20683950 | Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. | Hepatology | 2010 | https://conductscience.org/library/papers/20683950 | PubMed |
| 2 | 23526421 | On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development. | Hepatology | 2013 | https://conductscience.org/library/papers/23526421 | PubMed |
| 3 | 21179572 | Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. | PLoS One | 2010 | https://conductscience.org/library/papers/21179572 | PubMed |
| 4 | 18829528 | The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. | Cancer Res | 2008 | https://conductscience.org/library/papers/18829528 | PubMed |
| 5 | 16489004 | Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. | Cancer Res | 2006 | https://conductscience.org/library/papers/16489004 | PubMed |
| 6 | 19659896 | Experimental mouse models for hepatocellular carcinoma research. | Int J Exp Pathol | 2009 | https://conductscience.org/library/papers/19659896 | PubMed |
| 7 | 21204741 | AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? | Expert Opin Biol Ther | 2011 | https://conductscience.org/library/papers/21204741 | PubMed |
| 8 | 14529839 | Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. | Mol Ther | 2003 | https://conductscience.org/library/papers/14529839 | PubMed |
| 9 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 10 | 22797301 | Cholangiocarcinomas can originate from hepatocytes in mice. | J Clin Invest | 2012 | https://conductscience.org/library/papers/22797301 | PubMed |
| 11 | 20175036 | Mouse models of hepatocellular carcinoma. | Semin Liver Dis | 2010 | https://conductscience.org/library/papers/20175036 | PubMed |
| 12 | 11103822 | Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. | Cancer Res | 2000 | https://conductscience.org/library/papers/11103822 | PubMed |
| 13 | 12498772 | In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. | Mol Ther | 2002 | https://conductscience.org/library/papers/12498772 | PubMed |
| 14 | 14519650 | Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14519650 | PubMed |
| 15 | 23029524 | Bmi1 is required for hepatic progenitor cell expansion and liver tumor development. | PLoS One | 2012 | https://conductscience.org/library/papers/23029524 | PubMed |
| 16 | 17069969 | Molecular pathology of biliary tract cancers. | Cancer Lett | 2007 | https://conductscience.org/library/papers/17069969 | PubMed |
| 17 | 14507645 | Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. | Am J Pathol | 2003 | https://conductscience.org/library/papers/14507645 | PubMed |
| 18 | 16818635 | Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. | Cancer Res | 2006 | https://conductscience.org/library/papers/16818635 | PubMed |
| 19 | 19061838 | Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. | Cancer Cell | 2008 | https://conductscience.org/library/papers/19061838 | PubMed |
| 20 | 19319137 | Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. | Br J Cancer | 2009 | https://conductscience.org/library/papers/19319137 | PubMed |
Cited by265
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 343 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42928503 | In Vivo CRISPR Screen Identifies RPS19 as an Immunotherapy Target in Hepatocellular Carcinoma. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42928503 | PubMed |
| 42881192 | MAP2-mediated integrin dysregulation reprograms cancer cell plasticity in hepatocellular carcinoma. | Nat Commun | 2026 | https://conductscience.org/library/papers/42881192 | PubMed |
| 42792787 | Molecular Signaling Pathways, Regulatory and Coactivator Networks, and Emerging Mechanisms in Hepatocellular Carcinoma. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792787 | PubMed |
| 42784692 | Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer. | Science | 2026 | https://conductscience.org/library/papers/42784692 | PubMed |
| 42722692 | Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy. | Nat Commun | 2026 | https://conductscience.org/library/papers/42722692 | PubMed |
| 42468529 | Purine and pyrimidine-based bacterial cyclic dinucleotides egress the phagosome and activate the innate immune sensor STING. | Immunity | 2026 | https://conductscience.org/library/papers/42468529 | PubMed |
| 42306568 | Targeting SMYD2 improves immunotherapy response in experimental hepatocellular carcinoma. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42306568 | PubMed |
| 42303608 | AKAP1 enhances glycogen accumulation and hepatocarcinogenesis through YTHDF2-mediated G6PC mRNA decay. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42303608 | PubMed |
| 42259916 | Targeting cancer-specific mutations with RNA-triggered chromatin shredding. | Nature | 2026 | https://conductscience.org/library/papers/42259916 | PubMed |
| 42259775 | GABRD promotes hepatocellular carcinoma progression via the IL-10RA/JAK2-STAT3 signaling axis. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42259775 | PubMed |
| 42248845 | Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42248845 | PubMed |
| 42207634 | Chaperone-mediated autophagy is a tumor-suppressive mechanism in hepatocellular carcinoma. | Cell Rep | 2026 | https://conductscience.org/library/papers/42207634 | PubMed |
| 42156413 | Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypes. | Nat Commun | 2026 | https://conductscience.org/library/papers/42156413 | PubMed |
| 42146678 | Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding. | bioRxiv | 2026 | https://conductscience.org/library/papers/42146678 | PubMed |
| 42118142 | Development of Immunoelectron Microscopy for VASN Detection Using Multiple Models and Identification of VASN as a Key Regulator of Mitochondrial Homeostasis in Hepatocellular Carcinoma Cells. | FASEB J | 2026 | https://conductscience.org/library/papers/42118142 | PubMed |
| 42078198 | How to efficiently establish animal models of cholangiocarcinoma: challenges and inspiration. | Med Rev (2021) | 2026 | https://conductscience.org/library/papers/42078198 | PubMed |
| 42066073 | Chronic stress disrupts hepatic homeostasis and accelerates liver cancer progression through ADRB2 signaling. | Sci Adv | 2026 | https://conductscience.org/library/papers/42066073 | PubMed |
| 41950310 | SLC13A2-transported citrate remodels transcriptional regulation through protein acetylation to suppress tumor growth. | Sci Adv | 2026 | https://conductscience.org/library/papers/41950310 | PubMed |
| 41937186 | Overexpression of ONECUT1 suppresses hepatoblastoma progression via modulating tumor cell growth and tumor microenvironment. | Cell Biosci | 2026 | https://conductscience.org/library/papers/41937186 | PubMed |
| 41928626 | Co-repression of Yap1 and Sox9 abrogates established cholangiocarcinoma by eliminating transcriptional compensation. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41928626 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24480331
GET https://conductscience.org/api/papers/v1/24480331/references?page=2